Telix Pharmaceuticals Ltd has released a press release.
CMS proposes payment improvement for radiopharma diagnostics
Filed with ASX ·
Watch Telix Pharmaceuticals' latest callTelix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call · Replay · Aug 20Read the transcript of Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call6ix hasn’t read this filing yet.
Telix Pharmaceuticals Limited on 6ix
Earlier from Telix Pharmaceuticals
- Telix Elects to Withdraw from Proposed U.S. Listing
- Trading Halt
- Telix Launches Proposed US IPO
- Telix Completes TLX250-CDx (Zircaix) BLA Submission
- ProstACT SELECT Study of TLX591 rADC Therapy - Positive rPFS
Later from Telix Pharmaceuticals
- Telix Q2 2024 Revenue/Business Highlights, Guidance Upgrade
- Telix Announces A$600 Million Convertible Bonds Offering
- Telix Successfully Prices A$650M Convertible Bonds
- Convertible Bond Cleansing Notice
- Telix Completes A$650 Million of Convertible Bonds
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals